Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
Disease Category: Breast Cancer
Location: United States, CA
PHII-117, NCI #8822: Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients with Advanced Breast Cancer
The purpose of this study is to find out what effects, good and/or bad the combination of azacitidine and entinostat has on you and your breast cancer.
Azacitidine and entinostat are both anti-cancer agents. Azacitidine has been approved by the Food and Drug Administration for use in a type of cancer called myelodysplastic syndrome. Its use in breast cancer is still investigational. Entinostat is an experimental drug that has not been approved by the FDA, however the FDA have given us permission to use the drug for this study.
This study follows a previous trial with azacitidine and entinostat where some people with a different type of cancer than your cancer had a decrease in the size of their tumor. It is our hope that the combination of the two agents might increase the chance of benefiting you however we do not know whether this will be true.
People with measurable, locally advanced, inoperable breast cancer or metastatic breast cancer who progressed despite prior treatments are eligible to participate in this study. You will receive azacitidine and entinostat as long as your cancer is stable and does not grow, and the side effects of azacitidine and entinostat are not too hard on you, and you wish to continue.
Patient Inclusion/Exclusion Criteria:
- See http://clinicaltrials.coh.org for additional information.
City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)
Research Center Information: City of Hope
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these